Healio13h
GLP-1 does not slow Parkinson’s disease progression in phase 3 study
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
Ozempic-like drug fails to treat Parkinson's disease in new study; here's what the scientists said
A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...
Armed robbery in Revesby20h
GLP-1 Drug Offers Limited Aid for Parkinson's Patients
The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...
Becker's Hospital Review15h
GLP-1 drug fails to slow Parkinson's: Study
A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
Medical News Today1h
Whose cardiovascular health do SGLT2, GLP-1 diabetes drugs benefit most?
A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.
Medicine Buffalo11h
Ophthalmic complications in patients on antidiabetic GLP-1 medications are concerning neuro-ophthalmologists
A small percentage of patients taking GLP-1 medications have experienced vision problems, but a direct causal link with the ...
How Eli Lilly is approaching GLP-1 marketing and what’s next
Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...
Expert highlights importance of fluoride for oral and overall health
Fluoride not only strengthens teeth and leads to better health overall but also is one tool communities can use to reduce ...